BCL2 and glioblastoma: Subsequently, we computed the IC50 values for the selected drugs and observed that the IC50 for Navitoclax was significantly greater in class 1 than in class 2, as shown in Fig. 4F. In a recent study, the survival rate of mice with GBM treated with the ageing drug navitoclax, an inhibitor of the antiapoptotic proteins BCL2 and BCL-xL, significantly increased compared to control mice (WT + vhc) [35].